Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …

Dyslipidemia, specifically elevated low-density lipoprotein (LDL) cholesterol levels, causes
atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial …

Abundant evidence links elevated levels of lipoprotein (a)(Lp (a)) to higher cardiovascular
risk, leaving clinicians with the challenge of what measures to take to mitigate Lp (a) …

Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks
for the development and progression of cardiovascular diseases. These conditions are …

Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA
and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation …

Abstract Purpose of Review Patients with non-alcoholic fatty liver disease (NAFLD), often
considered as the hepatic manifestation of the metabolic syndrome, represent a population …

Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and
dyslipidemia is one of the major risk factors. Hypercholesterolemia is the most common form …

Prenyltransferases (PTases) are known to play a role in embryonic development, normal
tissue homeostasis and cancer by posttranslationally modifying proteins involved in these …